Bruno Fant

Company: myNEO Therapeutics

Job title: Chief Technology Officer

Seminars:

Bringing Novel Class of Vaccine Targets into Development – Camyopeptides Derived from Tumour-Specific IncRNAs 9:00 am

Results from the profiling of over 1500+ tumour biopts and neoantigen landscapes First glance at immunological responses revealing first-in-class potential of shared tumor targets Designing the mRNA-LNP cancer vaccineRead more

day: Day Two